CD274 and neoplasm: Many tumor cells, including NSCLC, overexpress PD-L1 to evade the immunological surveillance.[23,24] Accordingly, several drugs targeting this pathway have been developed, including the anti-PD-1 antibodies nivolumab (BMS-936558), AMP-224, pembrolizumab (MK-3475), and pidilizumab (CT-011), and the anti-PD-L1 antibodies MPDL3280A, MEDI-4736, and BMS-936559 (MDX-1105).